AAA
NUVB icon

Affinity Asset Advisors’s Nuvation Bio NUVB Stock Holding History

Affinity Asset Advisors’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-250,000
Closed -$378K – 112
2023
Q4 		$378K Hold
250,000
– – 0.07% 77
2023
Q3 		$335K Hold
250,000
– – 0.09% 75
2023
Q2 		$450K Hold
250,000
– – 0.16% 65
2023
Q1 		$415K Hold
250,000
– – 0.14% 67
2022
Q4 		$480K Buy
+250,000
New +$506K 0.19% 58

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Affinity Asset Advisors's NUVB Position: Q1 2024 in Review

Affinity Asset Advisors sold out of Nuvation Bio (NUVB) in Q1 2024, closing a stake of 250,000 shares — an estimated $378K sold.

Affinity Asset Advisors first reported a position in NUVB in Q4 2022 and held it in 5 quarters. The position peaked at $480K in Q4 2022. 124 funds tracked by Wall St. Rank hold NUVB as of Q1 2024.

  • Affinity Asset Advisors reported no remaining Nuvation Bio position as of Q1 2024 after selling out during the quarter.
  • Affinity Asset Advisors sold 250,000 Nuvation Bio shares in Q1 2024, an estimated $378K.
  • Affinity Asset Advisors first reported a position in Nuvation Bio in Q4 2022 and held it in 5 quarters.
  • Affinity Asset Advisors's Nuvation Bio position peaked at $480K in Q4 2022.
  • 124 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2024.

Based on Affinity Asset Advisors's 13F filing for Q1 2024, filed 14 May 2024.